Leonid Timashev
Stock Analyst at RBC Capital
(4.16)
# 458
Out of 5,147 analysts
155
Total ratings
54.68%
Success rate
12.44%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Outperform | $417 → $425 | $316.99 | +34.07% | 6 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Outperform | $47 → $45 | $30.10 | +49.50% | 6 | Feb 26, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $191 → $195 | $190.02 | +2.62% | 4 | Feb 25, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $219 → $222 | $163.89 | +35.46% | 16 | Feb 24, 2026 | |
| CYTK Cytokinetics | Maintains: Outperform | $95 → $101 | $62.22 | +62.33% | 7 | Feb 20, 2026 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $49 | $32.20 | +52.17% | 5 | Feb 18, 2026 | |
| CMPS COMPASS Pathways | Maintains: Outperform | $21 → $22 | $6.90 | +218.84% | 6 | Feb 18, 2026 | |
| EXEL Exelixis | Maintains: Sector Perform | $45 → $46 | $44.06 | +4.40% | 3 | Feb 11, 2026 | |
| CGON CG Oncology | Maintains: Outperform | $61 → $73 | $58.80 | +24.15% | 3 | Jan 21, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Outperform | $44 → $47 | $35.46 | +32.54% | 9 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $12 | $5.91 | +103.05% | 4 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $13 | $7.13 | +82.33% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $77 → $140 | $102.02 | +37.23% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $197 → $200 | $149.33 | +33.93% | 8 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $9 → $22 | $11.52 | +90.97% | 14 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 | $19.00 | +247.37% | 15 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $1.47 | +240.14% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $13 | $10.44 | +24.52% | 10 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.38 | +189.86% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $30.44 | +64.26% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $12.77 | +48.79% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $27 → $11 | $5.73 | +91.97% | 2 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.72 | +127.27% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $4.10 | +21.95% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $5.40 | +196.30% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $0.63 | +376.57% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $101.27 | -30.88% | 1 | Jan 23, 2025 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Outperform
Price Target: $417 → $425
Current: $316.99
Upside: +34.07%
Alkermes
Feb 26, 2026
Maintains: Outperform
Price Target: $47 → $45
Current: $30.10
Upside: +49.50%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $191 → $195
Current: $190.02
Upside: +2.62%
Axsome Therapeutics
Feb 24, 2026
Maintains: Outperform
Price Target: $219 → $222
Current: $163.89
Upside: +35.46%
Cytokinetics
Feb 20, 2026
Maintains: Outperform
Price Target: $95 → $101
Current: $62.22
Upside: +62.33%
IDEAYA Biosciences
Feb 18, 2026
Reiterates: Outperform
Price Target: $49
Current: $32.20
Upside: +52.17%
COMPASS Pathways
Feb 18, 2026
Maintains: Outperform
Price Target: $21 → $22
Current: $6.90
Upside: +218.84%
Exelixis
Feb 11, 2026
Maintains: Sector Perform
Price Target: $45 → $46
Current: $44.06
Upside: +4.40%
CG Oncology
Jan 21, 2026
Maintains: Outperform
Price Target: $61 → $73
Current: $58.80
Upside: +24.15%
NewAmsterdam Pharma Company
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $35.46
Upside: +32.54%
Jan 21, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $5.91
Upside: +103.05%
Jan 21, 2026
Maintains: Outperform
Price Target: $22 → $13
Current: $7.13
Upside: +82.33%
Jan 21, 2026
Maintains: Outperform
Price Target: $77 → $140
Current: $102.02
Upside: +37.23%
Jan 21, 2026
Maintains: Outperform
Price Target: $197 → $200
Current: $149.33
Upside: +33.93%
Jan 21, 2026
Upgrades: Outperform
Price Target: $9 → $22
Current: $11.52
Upside: +90.97%
Jan 20, 2026
Maintains: Outperform
Price Target: $66
Current: $19.00
Upside: +247.37%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.47
Upside: +240.14%
Nov 20, 2025
Upgrades: Outperform
Price Target: $6 → $13
Current: $10.44
Upside: +24.52%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.38
Upside: +189.86%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $30.44
Upside: +64.26%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $12.77
Upside: +48.79%
Oct 31, 2025
Downgrades: Sector Perform
Price Target: $27 → $11
Current: $5.73
Upside: +91.97%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $5.72
Upside: +127.27%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $4.10
Upside: +21.95%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $5.40
Upside: +196.30%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $0.63
Upside: +376.57%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $101.27
Upside: -30.88%